In a report released yesterday, Jason Butler from JMP Securities reiterated a Buy rating on Marinus (MRNS), with a price target of $21. The company’s shares closed yesterday at $3.75.
According to TipRanks.com, Butler is a 5-star analyst with an average return of 15.1% and a 52.0% success rate. Butler covers the Healthcare sector, focusing on stocks such as Aevi Genomic Medicine Inc, Adamas Pharmaceuticals, and Axovant Gene Therapies.
Marinus has an analyst consensus of Strong Buy, with a price target consensus of $18.13, which is a 383.5% upside from current levels. In a report issued on March 5, Jefferies also initiated coverage with a Buy rating on the stock with a $10 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $10.54 and a one-year low of $2.36. Currently, Marinus has an average volume of 1.1M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid.
